Literature DB >> 3290233

Test-of-cure stool cultures for traveler's diarrhea.

C D Ericsson1, H L DuPont, J J Mathewson, P C Johnson, F J de la Cabada, J A Bitsura.   

Abstract

Whether enteropathogens were eradicated or persisted in test-of-cure stool cultures from 251 patients with traveler's diarrhea, the durations of diarrhea were similar within the antimicrobial agent-treated (32 versus 33 h) and placebo-treated (82 versus 96 h) groups. Routine test-of-cure stool cultures can be useful for evaluating treatment failures and for assessing asymptomatic carriage of enteropathogens after treatment, but they are not mandated in the design of placebo-controlled antimicrobial treatment trials in traveler's diarrhea when the focus of the trial is clinical efficacy.

Entities:  

Mesh:

Year:  1988        PMID: 3290233      PMCID: PMC266517          DOI: 10.1128/jcm.26.5.1047-1049.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Isolation of enteric pathogens from asymptomatic students from the United States and Latin America.

Authors:  L K Pickering; H L DuPont; D G Evans; D J Evans; J Olarte
Journal:  J Infect Dis       Date:  1977-06       Impact factor: 5.226

2.  Effect of erythromycin on the fecal excretion of Campylobacter fetus subspecies jejuni.

Authors:  T Pitkanen; T Pettersson; A Pomka; T U Kosunen
Journal:  J Infect Dis       Date:  1982-01       Impact factor: 5.226

3.  Furazolidone versus ampicillin in the treatment of traveler's diarrhea.

Authors:  H L DuPont; C D Ericsson; E Galindo; L V Wood; D Morgan; J A Bitsura; J G Mendiola
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis.

Authors:  B J Anders; B A Lauer; J W Paisley; L B Reller
Journal:  Lancet       Date:  1982-01-16       Impact factor: 79.321

5.  Role of a novel antidiarrheal agent, BW942C, alone or in combination with trimethoprim-sulfamethoxazole in the treatment of traveler's diarrhea.

Authors:  C D Ericsson; P C Johnson; H L DuPont; D R Morgan
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

6.  Single-dose tetracycline therapy for shigellosis in adults.

Authors:  L K Pickering; H L DuPont; J Olarte
Journal:  JAMA       Date:  1978-02-27       Impact factor: 56.272

7.  Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial.

Authors:  C D Ericsson; P C Johnson; H L Dupont; D R Morgan; J A Bitsura; F J de la Cabada
Journal:  Ann Intern Med       Date:  1987-02       Impact factor: 25.391

8.  Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children.

Authors:  E Salazar-Lindo; R B Sack; E Chea-Woo; B A Kay; Z A Piscoya; R Leon-Barua; A Yi
Journal:  J Pediatr       Date:  1986-08       Impact factor: 4.406

9.  Bicozamycin, a poorly absorbable antibiotic, effectively treats travelers' diarrhea.

Authors:  C D Ericsson; H L DuPont; P Sullivan; E Galindo; D G Evans; D J Evans
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

10.  Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone.

Authors:  H L DuPont; R R Reves; E Galindo; P S Sullivan; L V Wood; J G Mendiola
Journal:  N Engl J Med       Date:  1982-09-30       Impact factor: 91.245

  10 in total
  4 in total

1.  Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study.

Authors:  H L DuPont; C D Ericsson; J J Mathewson; M W DuPont
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 2.  Rifaximin: a review of its use in the management of traveller's diarrhoea.

Authors:  Gayle W Robins; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Resistant pathogens as causes of traveller's diarrhea globally and impact(s) on treatment failure and recommendations.

Authors:  David R Tribble
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

4.  Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.

Authors:  Robert Steffen; Zhi-Dong Jiang; Mónica L Gracias Garcia; Prithi Araujo; Michael Stiess; Tanju Nacak; Roland Greinwald; Herbert L DuPont
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.